J KEVIN BUCHI Insider Trading Transactions
Get free email notifications about insider trading for J KEVIN BUCHI.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of J KEVIN BUCHI. J KEVIN BUCHI is Chief Executive Officer in BIOSPECIFICS TECHNOLOGIES CORP ($BSTCE) and Director in IMPAX LABORATORIES INC ($IPXL) and Director in ZIOPHARM ONCOLOGY INC ($ZIOP) and Director in EPIRUS Biopharmaceuticals, Inc. ($CRXX) and Director in STEMLINE THERAPEUTICS INC ($STML) and Director in Alexza Pharmaceuticals Inc. ($ALXA) and President & CEO in TETRALOGIC PHARMACEUTICALS CORP ($TLOG) and in Dicerna Pharmaceuticals Inc ($DRNA) and Director in Dicerna Pharmaceuticals Inc ($DRNA) and Director in Amneal Pharmaceuticals, Inc. ($AMRX).
Latest Insider Trading Transactions of J KEVIN BUCHI
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALXA, AMRX, BSTCE, DRNA, CRXX, IPXL, STML, TLOG, ZIOP
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 07 2021 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | M | 0.00 | 46,218 | 0 | 0 | |
May 07 2021 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 0.00 | 35,406 | 0 | 35,406 | |
May 07 2021 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Buy | M | 0.00 | 46,218 | 0 | 70,085 | 23.9 K to 70.1 K (+193.65 %) |
May 06 2021 | ZIOP | ZIOPHARM ONCOLOGY ... | BUCHI J KEVIN | Director | Option Exercise | A | 4.31 | 31,250 | 134,688 | 31,250 | |
May 06 2021 | ZIOP | ZIOPHARM ONCOLOGY ... | BUCHI J KEVIN | Director | Grant | A | 0.00 | 4,167 | 0 | 4,167 | 0 to 4.2 K |
Oct 13 2020 | ZIOP | ZIOPHARM ONCOLOGY ... | BUCHI J KEVIN | Director | Option Exercise | A | 2.76 | 146,190 | 403,484 | 146,190 | |
Jun 16 2020 | DRNA | Dicerna Pharmaceut ... | BUCHI J KEVIN | Director | Option Exercise | A | 21.61 | 21,000 | 453,810 | 21,000 | |
Jun 16 2020 | DRNA | Dicerna Pharmaceut ... | BUCHI J KEVIN | Director | Option Exercise | A | 0.00 | 4,666 | 0 | 4,666 | |
May 07 2020 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | M | 0.00 | 6,459 | 0 | 0 | |
May 07 2020 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 0.00 | 46,218 | 0 | 46,218 | |
May 07 2020 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Buy | M | 0.00 | 6,459 | 0 | 23,867 | 17.4 K to 23.9 K (+37.10 %) |
Oct 25 2019 | BSTCE | BIOSPECIFICS TECHN ... | BUCHI J KEVIN | Chief Executive Off ... | Option Exercise | A | 46.52 | 85,000 | 3,954,200 | 85,000 | |
Oct 25 2019 | BSTCE | BIOSPECIFICS TECHN ... | BUCHI J KEVIN | Chief Executive Off ... | Option Exercise | A | 46.52 | 85,000 | 3,954,200 | 85,000 | |
Oct 25 2019 | BSTCE | BIOSPECIFICS TECHN ... | BUCHI J KEVIN | Chief Executive Off ... | Option Exercise | A | 46.52 | 85,000 | 3,954,200 | 85,000 | |
Jun 21 2019 | DRNA | Dicerna Pharmaceut ... | BUCHI J KEVIN | Director | Option Exercise | A | 15.44 | 33,000 | 509,520 | 33,000 | |
May 08 2019 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | M | 0.00 | 6,107 | 0 | 0 | |
May 08 2019 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 0.00 | 6,459 | 0 | 6,459 | |
May 08 2019 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 14.05 | 28,044 | 394,018 | 28,044 | |
May 08 2019 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Buy | M | 0.00 | 6,107 | 0 | 17,408 | 11.3 K to 17.4 K (+54.04 %) |
Mar 29 2019 | DRNA | Dicerna Pharmaceut ... | BUCHI J KEVIN | Director | Option Exercise | A | 14.13 | 8,000 | 113,040 | 8,000 | |
Aug 15 2018 | DRNA | Dicerna Pharmaceut ... | BUCHI J KEVIN | Option Exercise | A | 14.76 | 25,000 | 369,000 | 25,000 | ||
Aug 15 2018 | DRNA | Dicerna Pharmaceut ... | BUCHI J KEVIN | Option Exercise | A | 14.76 | 25,000 | 369,000 | 25,000 | ||
May 08 2018 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 0.00 | 6,107 | 0 | 6,107 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 15.01 | 24,977 | 374,905 | 24,977 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 14.45 | 20,445 | 295,430 | 20,445 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 16.40 | 7,931 | 130,068 | 7,931 | |
May 08 2018 | AMRX | Amneal Pharmaceuti ... | BUCHI J KEVIN | Director | Grant | A | 0.00 | 11,301 | 0 | 11,301 | 0 to 11.3 K |
May 08 2018 | IPXL | Impax Laboratories ... | BUCHI J KEVIN | Director | Option Exercise | D | 14.45 | 20,445 | 295,430 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | BUCHI J KEVIN | Director | Option Exercise | D | 16.40 | 7,931 | 130,068 | 0 | |
May 08 2018 | IPXL | Impax Laboratories ... | BUCHI J KEVIN | Director | Sell | D | 0.00 | 3,281 | 0 | 0 | 3.3 K to 0 (-100.00 %) |
May 08 2018 | IPXL | Impax Laboratories ... | BUCHI J KEVIN | Director | Sell | D | 0.00 | 8,020 | 0 | 0 | 8 K to 0 (-100.00 %) |
May 17 2017 | IPXL | IMPAX LABORATORIES ... | BUCHI J KEVIN | Director | Option Exercise | A | 16.40 | 7,931 | 130,068 | 7,931 | |
May 17 2017 | IPXL | IMPAX LABORATORIES ... | BUCHI J KEVIN | Director | Grant | A | 0.00 | 3,281 | 0 | 11,301 | 8 K to 11.3 K (+40.91 %) |
Nov 28 2016 | IPXL | IMPAX LABORATORIES ... | BUCHI J KEVIN | Director | Option Exercise | A | 14.45 | 20,445 | 295,430 | 20,445 | |
Nov 28 2016 | IPXL | IMPAX LABORATORIES ... | BUCHI J KEVIN | Director | Grant | A | 0.00 | 8,020 | 0 | 8,020 | 0 to 8 K |
Jun 21 2016 | ALXA | Alexza Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | D | 5.13 | 20,000 | 102,600 | 0 | |
Jun 21 2016 | ALXA | Alexza Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | D | 4.35 | 12,500 | 54,375 | 0 | |
Jun 21 2016 | ALXA | Alexza Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | D | 1.28 | 12,500 | 16,000 | 0 | |
Jun 25 2015 | STML | STEMLINE THERAPEUT ... | BUCHI J KEVIN | Director | Option Exercise | A | 12.76 | 24,000 | 306,240 | 24,000 | |
Jun 25 2015 | STML | STEMLINE THERAPEUT ... | BUCHI J KEVIN | Director | Grant | A | 0.00 | 10,000 | 0 | 23,772 | 13.8 K to 23.8 K (+72.61 %) |
Jun 25 2015 | ALXA | Alexza Pharmaceuti ... | BUCHI J KEVIN | Director | Option Exercise | A | 1.28 | 12,500 | 16,000 | 12,500 | |
Jun 08 2015 | CRXX | EPIRUS Biopharmace ... | BUCHI J KEVIN | Director | Option Exercise | A | 6.39 | 9,000 | 57,510 | 9,000 | |
Mar 30 2015 | TLOG | TETRALOGIC PHARMAC ... | BUCHI J KEVIN | President & CEO | Buy | P | 4.23 | 5,000 | 21,148 | 330,714 | 325.7 K to 330.7 K (+1.54 %) |
Page: 1